Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib clinical trial of PM54 in Advanced Solid Tumors patients
2023-508644-22-00Phase 2Authorised
- Sponsor
- PharmaMar
- Start
- Feb 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, single-arm trial of PM54 in Nonhematologic neoplasms, sponsored by PharmaMar. Planned start Feb 2023; status: authorised.
02
Drugs
PM54
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-508644-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508644-22-00.